$SMMT News Article - Summit Therapeutics Reports Ridinilazole Significantly Improved Short and Longer-Term Quality of Life Measures in Patients with C. difficile Infection Compared to Standard of Care
https://marketwirenews.com/news-releases/summ...11308.html